Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment

N/ANot Yet RecruitingNCT07059910

Assiut University100 enrolled

Overview

Prevalence of thyroid disorders in patients with immune thrombocytopenic purpura and its impact on treatment

We investigate patients with ITP for screening of thyroid disorders and how to deal with it and effect of this on the ttt

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Immune Thrombocytopenic Purpura Thyroid Disorders

Interventions

Search for thyroid disordersDIAGNOSTIC_TEST

TSH , FT3 , FT4

Laboratory testDIAGNOSTIC_TEST

Search for anti thyroid antibodies

Steroid and eltrombopageDRUG

See when we treat thyroid disorders, will patient respond to steroid or eltrombopage?

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ITP patients will be classified as newly diagnosed, persistent and chronic based on duration less than 3 months, 3-12 months, and more than 12 months respectively. * refractory ITP patients. Exclusion Criteria: * patients with history of thyroidectomy * patients with history of drug induced ITP * patients with history of HCV, HBV and HIV infection. * Patients who refuse to contribute in this study.

Outcomes

Primary Outcomes

Assess the frequency of thyroid disorders in patients with IT

Screening of thyroid disorders in patients with ITP

Time frame: Assess the frequency of thyroid disorders in patients with IT

Evaluate the treatment of thyroid disorders in improvement in platelets count.

Evaluate if patients have managed according to thyroid disorders, will this affect in their response to ITP management

Time frame: Evaluate the treatment of thyroid disorders in improvement in platelets count.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.